Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 12, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - December 12, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/12/17 - 42 Biggest Movers From Yesterday
Gainers Yield10 Bioscience Inc shares jumped 183.59 percent to close at $5.53 on Monday after the company reported granting of research license to Monsanto for evaluation of 2 novel yield traits in soybean. ARGENX SE/ S ADR shares climbed 78.88 percent to close at $54.47 after the company reported positive topline results from Phase 2 proof-of-conc
12/12/17 - AbbVie Announces Phase 3 Study of VENCLEXTA?/ VENCLYXTO? (venetoclax) in Combination with Rituxan (rituximab) Meets its Primary Endpoint
AbbVie, a research and development based global biopharmaceutical company, today announced the first presentation of efficacy and safety results from MURANO, an international, multicenter, open-label, randomized Phase 3 study of VENCLEXTA?/ VENCLYXTO? in combination with Rituxan compared with bendamustine in combination with Rituxan in pat
12/12/17 - Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology
CAMBRIDGE- Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced preliminary results from the ongoing Phase 2 trials with luspatercept in patients with lower-risk myelodysplastic syndromes at the 59th Annual Meeting of the American...
12/12/17 - Acer Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
Acer Therapeutics Inc., a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced the pricing of its underwritten public offering of 916,667 shares of its common stock at a public offering price of $12.00 per share.
12/12/17 - ADHD Therapeutics Market Healthy Growth Rate by Top Players, Major Types, Revenue and Forecasts Till 2024
ADHD Therapeutics Market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East& Africa. Concordia International Corp., Eli Lilly and Company, Highland Therapeutics Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven Pharmaceuticals Inc., Pfizer
12/12/17 - ADMA Files Biologics License Application For Its Third Plasma Collection Center [Algeria Press Service]
ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease and the prevention and treatment of certain infectious diseases, announces the filing of a Biologics License Application for its third...
12/12/17 - Affordable Medicines
Drug prices are too high, and Congress lacks the political will to do anything about it. Yet Congress has failed to take up these proposals, and the prospects are dim for legislation anytime soon. So two states, Massachusetts and Arizona, have asked the federal government for permission to pick and choose which drugs they will cover for Medicaid be
12/12/17 - Agency Information Collection Activities: Submission for Office of Management and Budget Review; Comment Request; Applications for Food and Drug Administration Approval To Market a New Drug
All comments should be identified with the OMB control number 0910-0001. Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Under section 505 of the Fede
12/12/17 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Orphan Products Development; Food and Drug Administration Orphan Drug Designation Request Form and The Common European Medicines Agency/
All comments should be identified with the OMB control number 0910-0167. Also include the FDA docket number found in brackets in the heading of this document. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Sections 525 through 528 of t
12/12/17 - Allergan Receives FDA Clearance For the CoolSculpting Treatment To Improve Appearance Of Lax Tissue In The Double Chin
Allergan plc today announced that the CoolSculpting treatment is the first and only non-surgical fat reduction technology to be FDA- cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments. "A 2017 American Society for Dermatologic Surgery survey revealed that 73 percent of patients are both
12/12/17 - Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of adults with hereditary transthyretin-mediated amyloidosis.
12/12/17 - Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs
CINCINNATI and CAMBRIDGE, England, Dec. 12, 2017/ PRNewswire/ Aprecia Pharmaceuticals, LLC, The 3 DP Pharmaceutical Company, and Cycle Pharmaceuticals, Ltd. today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed technology. The planned products will deliver quality-of-l
12/12/17 - ARROWHEAD PHARMACEUTICALS, INC. - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Unless otherwise noted, the term "Arrowhead" refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation, the terms "Company," "we," "us," and "our," refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, the term "Subsidiaries" refers collectively to Arrow
12/12/17 - AstraZeneca's CALQUENCE demonstrates activity in relapsed or refractory mantle cell lymphoma trial
AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration accelerated approval of CALQUENCE. CALQUENCE was granted accelerated approval by the US Food
12/12/17 - AstraZeneca's CALQUENCE shows potential in chronic lymphocytic leukemia trials
AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial and updated results from the Phase I/II ACE-CL-001 clinical trial that are evaluating acalabrutinib alone and in combination for the treatment of chronic lymphocytic leukemia in multiple
12/12/17 - AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission
AXIM Biotechnologies, Inc., a world leader in cannabinoid research and development, announced today that it has successfully completed a pre-investigational New Drug Application meeting with the U.S. Food and Drug Administration for a dronabinol-based functional, controlled-release chewing gum product it s developing to help treat patients
12/12/17 - BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib Combined with GAZYVA at the 59th American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. and BEIJING- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today presented updated preliminary clinical data from an ongoing Phase 1 b trial of its investigational Bruton's Tyrosine Kinase..
12/12/17 - BioElectronics Announces ActiPatch: Over-The-Counter Alternative to Opioids
BioElectronics Corporation, the maker of advanced wearable consumer pain management medical device, ActiPatch, announced today the launch of ActiPatch for Over-The-Counter, drug-free pain relief as an alternative to Opioids. ActiPatch is approved by the FDA for Over-The-Counter sales for the adjunctive treatment of pain due to: 1) Osteoarthritis
12/12/17 - BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
SAN RAFAEL- BioMarin Pharmaceutical Inc. announced today an update to its previously reported results of an open-label Phase 1/ 2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for severe hemophilia A. The updated results will be presented during an oral presentation at the 59th American Society of Hematology Annual.
12/12/17 - BioPharmX Reports Third Quarter 2018 Financial Results
MENLO PARK, Calif.- BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, today announces its financial results for the third quarter ended October 31, 2017. 'We achieved important regulatory and financial milestones during the quarter,' said BioPharmX president Anja Krammer.' The Food and Drug Administration concurred
12/12/17 - Boehringer Ingelheim Marks Great Progress in Immuno-Oncology Research Partnerships in 2017
INGELHEIM AM RHEIN, Germany, Dec. 11 Boehringer Ingelheim, a pharmaceutical company, issued the following news release:. 2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. "In the immuno-onco
12/12/17 - Botanical and Plant-Derived Drugs - Analysis, Trends & Forecasts to 2022 - Research and Markets
The "Botanical and Plant-Derived Drugs: Global Markets" report has been added to Research and Markets' offering. The Global Market for Botanical and Plant-Derived Drugs will Grow from $29.4 Billion in 2017 to around $39.6 Billion by 2022 with a CAGR of 6.1%.. For the purposes of this report, botanicals are those drugs that are FDA- approved under t
12/12/17 - CAR T, Immunotherapy Bring New Hope for Multiple Myeloma Patients
The University of Pennsylvania's Perelman School of Medicine issued the following news release:. Researchers from the University of Pennsylvania's Abramson Cancer Center administered CAR T cells to patients following chemotherapy, with 64 percent of patients responding in a clinical trial. These studies will be presented as oral abstracts at the 59
12/12/17 - Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
-Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that its affiliate Correvio has entered into an exclusive license and distribution agreement with ZAO Firma Euroservice that will advance Aggrastat toward commercialization in Russia.
12/12/17 - Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy
SUMMIT- Celgene Corporation and bluebird bio, Inc. today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415